Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Emigh Insider Profile
4 Followers
James Emigh, VP & Corp. Dev at Acura Pharmaceuticals, holds 474.04K shares in Acura Pharmaceuticals (Ticker: ACUR).
James Emigh Acura Pharmaceuticals (ACUR)VP & Corp. Dev
Acura Pharmaceuticals (ACUR)
VP & Corp. Dev
Ranked #88,644 out of 98,501 Corporate Insiders
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-52.30%
Average return per transaction
Time Frame
Compare to
Insider Roles
VP & Corp. Dev
Roles that James Emigh holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:May 16, 2014 - May 16, 2015
Return:-34.80%
The most profitable trade made by James Emigh
James Emigh's Trading History
List of latest transactions for each holding click on a transaction to see James Emigh's performance on stock
You May Also Like
James Emigh insider profile FAQ
What is the percentage of profitable transactions made by James Emigh?
The percentage of profitable transactions made by James Emigh is 0%.
What is the average return per transaction made by James Emigh?
The average return per transaction made by James Emigh is -52.30%.
What stocks does James Emigh hold?
James Emigh holds: ACUR stocks.
What was James Emigh’s latest transaction?
James Emigh latest transaction was an Uninformative Sell of $3.02K.
What was James Emigh's most profitable transaction?
James Emigh’s most profitable transaction was an Informative Buy of ACUR stock on May 16, 2014. The return on the trade was -34.80%.
What is James Emigh's role in Acura Pharmaceuticals?
James Emigh's role in Acura Pharmaceuticals is VP & Corp. Dev.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.